SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust Series 1 ($QQQ) is experiencing high volatility as traders grapple with mixed signals and a sharp intraday reversal. Community discussions center around potential market manipulation, the impact of $NVDA's earnings, and speculation about future interest rate decisions. Some traders are anticipating a bounce, while others fear a deeper correction, creating uncertainty around the direction of the tech-heavy ETF.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as investors discuss its latest earnings report, with community members debating whether positive results will be enough to overcome negative market sentiment. Discussions also include speculation about potential upgrades, institutional interest, and comparisons to similar companies like SoFi. Some traders are closely watching for guidance from the earnings call and anticipate increased volatility.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending downwards, with community members expressing concerns about the stock's performance relative to ETH and overall crypto market conditions. Disappointment and frustration are directed towards figures like Tom Lee, with skepticism surrounding price predictions and strategic decisions. Investors are closely watching for potential earnings catalysts or staking strategy announcements that could shift momentum.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid a sharp market reversal driven by concerns about future rate cuts and disappointing reactions to tech earnings, sparking community discussion on potential support levels and market manipulation. Community members are debating whether this is a temporary pullback or the start of a larger correction, with some pointing to potential negative catalysts while others anticipate a bounce. Discussions also involve the impact of political factors and the unwinding of carry trades on market sentiment.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as traders assess its recent pullback and potential for a rebound, with some noting its relative strength compared to tech. Community members are actively discussing key support and resistance levels, put/call flows, and the potential impact of upcoming economic data and $NVDA earnings on small caps. Overall sentiment appears mixed, with both bullish and bearish viewpoints being shared.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid a volatile trading session, driven by reactions to increased capital expenditure plans and anticipation for Nvidia's upcoming earnings report. Community members are actively debating whether the recent pullback presents a buying opportunity or signals an overbought condition, with some citing strong fundamentals and rising memory prices, while others point to potential overvaluation and cyclical concerns within the semiconductor sector.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors assess its stability amid broader market uncertainty and an upcoming earnings report, with some highlighting its potential to capture market share from competitors. The community is also discussing Walmart's AI initiatives and the impact of consumer spending trends on its performance. Additionally, Walmart's recent announcement of a CEO transition is being monitored for its potential impact on the company's strategic direction.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending downwards as Bitcoin's recent volatility sparks concerns about the company's heavy investment in the cryptocurrency and potential margin calls. The community is actively discussing downside risk, potential bankruptcy scenarios, and the impact of prominent figures like Jim Cramer and Michael Saylor on the stock's future, questioning its correlation with Bitcoin's price movements.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards as the broader crypto market experiences a pullback, sparking discussions about potential support levels and whether this is a temporary dip or a longer-term correction. The community is debating the influence of large holders and potential market manipulation, while also considering historical patterns and future catalysts. Some traders are expressing concern and urging caution, while others see this as a buying opportunity.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, with the community debating potential causes such as market manipulation, overall market conditions, and concerns about profitability ahead of earnings; some traders are pointing to the company's recent news regarding its AI chip, while others express frustration with the stock's performance despite positive developments for the EV maker.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.</li><li>The company raised $12 million through convertible notes, with potential total proceeds of $58 million if all warrants are exercised, strengthening its balance sheet.</li><li>Retail investors on Stocktwits turned bullish on the news, calling Femasys a long-term play with disruptive potential in women’s health.</li></ul>Retail chatter around Femasys spiked on Monday following the company’s announcement that it secured U.S. Food and Drug Administration (FDA) approval to advance the final phase of its pivotal trial for FemBloc, a non-surgical permanent birth control device, and raised $12 million in financing that could grow to $58 million if all warrants are exercised.<h2 class="st-heading-2">FDA Clears Final Phase Of FemBloc Trial</h2>Femasys announced FDA approval to resume enrollment for the final phase of the FemBloc pivotal FINALE trial, allowing it to move closer to U.S. Pre-Market Approval (PMA).The Investigational Device Exemption (IDE) approval came following the successful completion of the trial’s first stage, advancing the commercialization of the world’s first non-surgical, permanent birth control in the U.S.FemBloc uses a polymer-based delivery system that blocks the fallopian tubes without incisions or anesthesia, offering a safer and lower-cost alternative to surgical sterilization.<h2 class="st-heading-2">Financing Deal With Potential Upside To $58 Million</h2>Alongside the FDA update, Femasys entered into a private placement agreement with institutional and accredited investors, led by Jorey Chernett, to issue $12 million in senior secured convertible notes and warrants,&nbsp;with the potential to raise total proceeds to $58 million if exercised for cash.The company said proceeds will go toward refinancing debt and advancing&nbsp;the commercialization of its fertility and permanent birth control portfolio.The notes carry an 8.5% annual interest rate and are convertible at $0.73 per share, a 15% premium to the stock’s prior closing price. Warrants carry exercise prices between $0.81 and $1.10 per share, with 10-year terms.<h2 class="st-heading-2">Stocktwits Users Cheer Regulatory Win</h2>On Stocktwits, retail sentiment for Femasys was ‘bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:969/142;" src="https://news.stocktwits-cdn.com/femy_ss_jpg_e7ab6d375e.webp" alt="femy ss.jpg" width="969" height="142"><figcaption>FEMY sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed Femasys as a long-term play, describing its regulatory progress and disruptive women’s health products as strong growth drivers. The user added that the company’s performance is likely to move “based on fundamentals” rather than hype, noting that women’s health remains an underappreciated sector.<stembedurl>https://stocktwits.com/CoconutNinja/message/634760377</stembedurl>Another user speculated whether the stock would see after-hours upside following the positive news.<stembedurl>https://stocktwits.com/steve04240/message/634739416</stembedurl><a href="https://stocktwits.com/symbol/FEMY">Femasys’ stock</a> has declined 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Femasys logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing

Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.

Equity

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Femasys Inc. (FEMY) traded 17% lower on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/30/3091024/0/en/Femasys-Announces-Pricing-of-Underwritten-Public-Offering-and-Concurrent-Private-Placement-with-Gross-Proceeds-of-4-5-Million.html">announced</a> the pricing of an underwritten public offering of 3.6 million shares of its common stock at $0.85 per share.The offer price represents a discount of about 17% from the stock’s closing price on Thursday.The company also announced a separate concurrent private placement of approximately 1.7 million shares of its common stock at the same price as sold to certain existing institutional stockholders of Femasys, as well as a price of $1.02 per share to certain of its directors and officers.The gross proceeds of the public offering and private placement to Femasys are expected to be about $4.5 million.The company stated that it intends to use the net proceeds for the expansion of its commercial efforts, the development of its products and product candidates, general corporate purposes, capital expenditures, working capital, and general and administrative expenses.Both the public offering and the private placement are expected to close on or about June 2 and are subject to the successful completion of customary closing conditions.On Stocktwits, the retail sentiment around Femasys jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_8_59_37_AM_png_3daa1e0a3d.webp" alt="FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company and said they will buy shares in the short term.<stembedurl>https://stocktwits.com/Mirto/message/616299906</stembedurl>Another user, however, expressed concerns about the stock falling below $1.<stembedurl>https://stocktwits.com/goldenxb/message/616299012</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY stock</a> is down by over 23% this year and by about 28% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-dell-to-build-doe-s-doudna-supercomputer/ch0MD6bRbuG">Nvidia, Dell To Build DOE’s Doudna Supercomputer – ‘Time Machine for Science,’ Says Jensen Huang</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up

The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Shares of Femasys Inc. (FEMY) tumbled nearly 14% on Thursday after the company’s 2024 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.femasys.com/news/news-details/2025/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2024-and-Provides-Corporate-Update/default.aspx">earnings</a> fell below Wall Street estimates.The company reported a 52% jump in annual sales to $1.62 million compared to 2023, but failed to meet an analyst estimate of $2.71 million, according to FinChat data.The loss per share of $0.85, though lower than the $0.93 reported in 2023, exceeded an estimated loss of $0.80.The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.Femasys said its current cash and cash equivalents, which includes approximately $5.4 million raised subsequent to year-end, will be sufficient to fund its ongoing operations into third quarter of 2025.The company focuses on addressing critical unmet needs in women’s health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products.Femasys CEO Kathy Lee-Sepsick said that the company is focused on commercializing FemaSeed, its first-line infertility treatment, and expects U.S. revenue to increase by about 50% in the first quarter of 2025 compared to the previous quarter.“We are continuing to advance our FemBloc to commercialization in Europe while executing on the clinical pivotal trial for U.S. FDA approval,” she added. FemBloc is the company's non-surgical permanent birth control.On Stocktwits, retail investor sentiment about Femasys dropped slightly in the ‘bullish’ territory (56/100) while message volume dropped from ‘high’ to ‘normal’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:651/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_1_54_06_PM_png_ca980a7546.webp" alt="FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits" width="651" height="151"><figcaption>FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user noted the company’s increase in annual sales and opined that the company is “heading in the right direction for sure.”<stembedurl>https://stocktwits.com/stoneblood/message/609410856</stembedurl>Another user highlighted they were buying the stock.<stembedurl>https://stocktwits.com/Mirto/message/609411502</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY shares</a> have gained over 19% this year but have lost nearly 11% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/microalgo-stock-surges-after-wimi-hologram-cloud-expands-stake/chJ2ah6RbEB">MicroAlgo Stock Surges After WiMi Hologram Cloud Expands Stake, Locking In Shares For 10 Years – Retail Hopes For Another Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic

The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.

EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says

Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
read more...

Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Femasys (FEMY Research Report). The associated price target remains the...

Femasys price target raised by $2 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

FEMY
Femasys Inc

Feed

News

Sentiment

Fundamentals

Info

Latest FEMY News

FEMYFemasys Inc